Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but
the optimum duration of treatment and best partner drug are uncertain. A randomized …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Background The optimal dosing of primaquine to prevent relapsing Plasmodium vivax
malaria in South Asia remains unclear. We investigated the efficacy and safety of different …

Background. A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has
shifted first-line treatment to artemisinin-based combination therapies, combined with …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Background Tafenoquine, co-administered with chloroquine, is approved for the radical cure
(prevention of relapse) of Plasmodium vivax malaria. In areas of chloroquine resistance …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of
Plasmodium vivax malaria, but this is rarely implemented because of concerns over …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria
despite increasing reports of treatment failure. We did a systematic review and meta …